Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anakinra + doxycycline
- Development stage
- Preclinical
- Lead developer
- Sobi
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Oral
01
Overview
Anakinra + doxycycline is a combination therapy that pairs an interleukin-1 receptor antagonist (anakinra) with a tetracycline antibiotic (doxycycline). Anakinra works by binding to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta, thereby reducing inflammation. Doxycycline is known to suppress inflammatory responses in the skin through incompletely understood mechanisms without exerting substantial systemic immunosuppressive effects. This combination has shown efficacy in treating atypical skin manifestations in Adult-Onset Still's Disease (AOSD) and has been investigated for potential benefits in COVID-19 pneumonia.
02
Targets
Beyond the preview
Go deeper on anakinra + doxycycline.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anakinra + doxycycline.